Pharm-Olam International Announces $13.4 Million Contracts to Provide Services for Clinical Trials
Pharm-Olam International Ltd. (POI), a multi-national CRO to pharmaceutical, biotechnology and medical device industries, announced the signing of three contracts with an aggregate value of $13.4 million. The contracts involve patient recruitment, site selection, project management, biostatistics, monitoring, and regulatory affairs in the therapeutic areas of pain, cardiovascular disease, and ophthalmology. - January 11, 2006
Pharm-Olam International Releases Results of 2005 Client Satisfaction Survey
Revealing continuing improvement in levels of customer satisfaction and loyalty, Pharm-Olam International Ltd. (POI), a multi-national CRO to pharmaceutical, biotechnology, and medical device industries, has released the most recent results of its formal survey. - December 09, 2005
Pharm-Olam International Completes Enrollment of 700 Patient Global Pivotal Phase III Clinical Trial for Metastatic Breast Cancer
HOUSTON, TEXAS – November 27, 2005 – Pharm-Olam International Ltd. (POI) has completed enrollment of a 700 patient pivotal trial for the treatment of metastatic and recurrent breast cancer. Enrollment of the Phase III clinical trial was achieved on schedule in just 18 months and... - November 25, 2005